Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FCN-159 in histiocytic neoplasms
ChiCTR2300067955Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luvometinib in histiocytic disease, Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective response rate. Started Apr 2022; status: recruiting.
02
Drugs
luvometinib
03
Conditions
histiocytic diseaseLangerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on ChiCTR2300067955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067955.